MUNDIPHARMA WINS “BEST COMPANY IN AN EMERGING MARKET”

December 7, 2016 - 3 minutes read
  • The Scrip Awards are the leading global awards for the pharmaceutical sector and recognize excellence and responsibility.
  • Mundipharma’s win further enhances its status as a leader in emerging markets.

December 2, 2016, Singapore – Singapore-based Mundipharma, has received the award for “Best Company in an Emerging Market” at the 12th annual Scrip Awards held at the Grosvenor House Hotel, Park Lane in London on November 30.

The Scrip Awards recognize and celebrate responsible companies and people in the pharmaceutical industry that help improve healthcare for people around the world.

This award is a reflection of Mundipharma’s dedication to improving access to essential medicines and innovation for patients living in countries with healthcare systems that are less advanced than those in other parts of the world.

In pursuing this objective, and its correlating mission of improving patients’ quality of life, Mundipharma has, this year alone, been recognised for its work numerous times. As well as the Scrip award, Mundipharma has won Company of the Year at the IAIR Awards, Company of the Year and Leader of the Year at the CMO Awards and its President, Raman Singh, was ranked the world’s fourth most influential person in the pharmaceutical industry by the UK’s Medicine Maker – the only Asian-based person in the top five.

“We are proud to be acknowledged as a company that works to support the growth and advancement of our industry beyond its traditional geographical borders.” said Raman Singh, President, Mundipharma Asia Pacific, Latin America the Middle East and Africa. “Mundipharma is passionately committed to bringing innovative, effective and safe treatments to patients everywhere. There are great unmet needs in this region and it is our responsibility as a company to harness innovation to provide patients with easier access to therapeutic strategies to improve the quality of their lives.”

ENDS

About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, ophthalmology, respiratory disease, rheumatoid arthritis and antiseptics.